Moderna’s Post

Disparities in healthcare access based on factors like race, ethnicity, and socioeconomic status contribute to unequal cancer outcomes. Join the FDA Oncology Center of Excellence for a Conversation on Cancer virtual public panel discussion on April 23: Strength in Numbers - Increasing Awareness, Decreasing Disparities. Register here to receive webinar link: https://lnkd.in/dREXNdEE

Understanding what truly happens during doctor-patient conversations can revolutionize patient care. In this video, witness how an oncologist explains the survival benefits of Tagrisso, showcasing the power of communication in guiding treatment decisions. At ZoomRx, we delve deep into these critical interactions through our HCP-Pt Conversation research—unlocking actionable insights that help life sciences companies craft patient-centered strategies. As we mark Lung Cancer Awareness Month, explore how these insights are transforming the fight against lung cancer in our latest blog: https://bit.ly/3OijWNj #lungcancerawareness #doctorpatientdialogue #hcp #pharma #healthcareconsulting #zoomrx #healthcareresearch #lungcancer

🔬 Day four at the 2024 ASCO Annual Meeting! It’s great to be here and engage in transformative discussions with industry leaders and oncology professionals. Excited to (re)connect and absorb insights that drive cancer care forward. Attendees are invited to book a meeting with us today and hear more on a decade's worth of breakthroughs in global patient access, courtesy of Karlijn Doorn, PhD and Daniele Tagliente. https://lnkd.in/epdyrvHn From pioneering expanded access programs (#EAPs) to harnessing real-world data (#RWD), we're here to revolutionize access and participation in clinical trials. We're open to discussions about collaborations that leave a lasting impact. #ASCO2024 #Oncology #RealWorldData #ExpandedAccess

Disparities in healthcare access based on factors like race, ethnicity, and socioeconomic status contribute to unequal cancer outcomes. Join the FDA Oncology Center of Excellence for a Conversation on Cancer virtual public panel discussion on April 23: Strength in Numbers - Increasing Awareness, Decreasing Disparities. Register here to receive webinar link: https://lnkd.in/dREXNdEE

This is one of the single, most important initiatives taking place right now. It is imperatitive that every organization doesn’t just know the details involved with this, but can execute this methodology. It starts with a comprehensive understanding of the draft guidance given in June of 2021, from this same office. How you set up the clinical trial is second to how you recruit the patients. I have found very few that grasp, or understand these two, when consulting. The future of every organization’s success will soon hinge upon that organization’s vision, strategy, and execution. The ability to simulate the study on the front end will be the most critical point of all of this. Better have the right vendors as partners. Good luck to everyone! #FEWUNDERSTAND

There are so many important messages in this, from importance of co-creation and including patients in trial design to the importance of leadership endorsing activities to enable the organisation to create more inclusive research 🌟.

Patients and society won’t reap the benefits of precision oncology unless we democratize this data, that is, make it available to the patients who need it when they need it. With a few practical improvements to current care pathways, we could achieve this, meet the need for urgency, and empower patients. Stacy Hurt 🌻, Parexel's Chief Patient Officer and a stage 4 cancer survivor, highlights three things we MUST do to ensure all patients can potentially benefit from precision oncology in our New Medicines, Novel Insights report: https://lnkd.in/gBkJMKt2 #PrecisionOncology #NovelInsights #PatientsFirst #PatientData #ASCO24

In this featured podcast from Pfizer published in Oncology and Therapy, our Vice President of Partnerships and breast cancer survivor, Rita Lusen, shares her patient perspective in a critical discussion with Brian Dong, MD, medical oncologist from the UofL Health James Brown Cancer Center, on the importance of shared decision-making in treatment selection, such as using a CDK4/6 inhibitor + an aromatase inhibitor in patients with HR+/HER2- metastatic breast cancer. Discussion highlights include:  ✅ Tailoring conversations to individual needs and treatment choices ✅ Tips for successful shared decision-making discussions  ✅ Real-life examples of shared decision-making Listen now: bit.ly/3Q1nhli Together, we can empower patients and promote shared decision-making in healthcare! 🤝

The push to treat patients with precision medicine techniques has driven the expansion of clinical research in oncology. Today, the need for centralized, connected data is greater than ever. Q-Centrix Vice President, Oncology Market Lead, Karen Schmidt, and Senior Vice President, Data and Research Victor Wang, explore the growing connection between oncology data management and research in our latest expert Q&A: https://bit.ly/3HOFKwG If you're attending #ACE2024, we invite you to continue the discussion with Victor and Karen in person—Booth 302! If you're not attending, reach out to us directly at [email protected] to learn more. Association of Cancer Executives #OncologyData #ClinicalResearch #ClinicalDataManagement

📣Today, we celebrate International Clinical Trials Day, a day dedicated to highlighting the crucial role of research in advancing medical treatments. We share the story of Ana María, a 79-year-old from Buenos Aires, Argentina, who is participating in a clinical trial investigating new treatment options for muscle-invasive bladder cancer 👏 Share your thoughts or experiences in the comments below. #ClinicalTrialsDay #BladderCancerResearch #BladderCancer #BladderCancerMonth24